Terms of Use

Translational Research & Strategic Services 

Kinexum guides, designs, and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical,  clinical development, and business challenges necessary to take scientific discoveries to proof of concept and through the product life cycle.

Kinexum teams supplement the strengths of large and small organizations to reach high-value milestones effectively and efficiently.  Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities, and business stages. We respond to emergencies and as well as requests for problem prevention and complex long-range planning. 

 


News and Upcoming Events 

 

BioEurope2019


 

WCITD2019


 

ADA2019


 

EASD2019


Kinexum executives and leading experts will attend the conferences in this section.  Anyone interested in meeting with them, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. .

If you missed our 2/6/19 webcast, a video of the presentation can be found at:

Kinexum-Hogan Lovells Webcast: Targeting Metabesity

 

Recent Articles

The Silent Epidemic of Diabetes in China by Tom Hedberg

BACKGROUND

There are frequently heavy prices to pay for cultures embracing the lifestyle of Western nations, particularly of the US. China’s rapid economic and social expansion during the past 30 years has led to unwanted and heretofore unknown health consequences. The first epidemiological investigation of diabetes in China in 1980 showed a diabetes prevalence of 1%. By 2009, however, that prevalence had grown to 10%, and diabetes has since become the third largest chronic disease in China after cancer and cardiovascular pathologies.1 According to the International Diabetes Federation, while diabetes is skyrocketing in China, the nation is still largely unprepared for the expected increase in diabetes-related comorbidities and complications. Fortunately, these complications have not yet become as widespread as the core disorder.

Read more...

Early NDA Planning for Small to Mid-sized Companies by Susan Manley

The final phase 3 studies are ongoing with a planned completion in 12 to 18 months. Your board is looking to the submission date with great excitement. Your company has made it this far – is time to relax? No, not yet! Your company has not prepared a US NDA in several years or, even more concerning, has never prepared an NDA. What can you do now to ensure a smooth trip to the submission and beyond?  

Read more...

Applications of Machine Learning in Healthcare: Scalable Treatment Solutions for Cancer Patients by Michael Cobb

A decade ago, Ms. Gitika Srivastava and Dr. Naresh Ramarajan learned that their close relatives had been diagnosed with cancer. In response, the two co-founded a company that uses machine learning to transform how patients make cancer treatment decisions. 

There are many barriers to democratize access to cancer care. Finding the right diagnosis, the best doctors, and the most applicable treatment is already a challenging task for patients with access to insurance and healthcare resources in developed countries. In developing countries, such as India, each of these tasks becomes exponentially more difficult.

Read more...

Strategies to Approaching CMC New Product Development and Manufacturing Outsourcing Resources by David Bergstrom

If your company is developing a new product, your team will—at some point—have to consider a CMC (Chemistry, Manufacturing & Controls) and outsourcing strategy. How should your company develop such a strategy?

Business Model and Corporate Strategy

 

Read more...

A Perspective on the Development of the Treatment of Our Next Epidemic - Brian Harvey, MD, Ph.D

Background 

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world [1]. The phenotypes of the disease extend from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), the latter of which progresses to liver fibrosis and end-stage cirrhosis [2]. 

Read More

Terms of Use

This web site may contain other proprietary notices and copyright information, the terms of which must be observed and followed. Information on the site may contain technical inaccuracies or typographical errors. Kinexum may make improvements and/or changes in the information or programs described at any time without notice.

Global availability:

Information published on this site may contain references to Kinexum programs and services that are not announced or available in countries outside the United States. Such references do not imply an intent to make such products, programs, or services available in specific countries and require communication with Kinexum's corporate office for specific information.

Third-party web sites:

Kinexum makes no representation whatsoever about any other web site which may be accessed through this site, and does not accept any responsibility for the content or use of such web site.

Limited License:

Subject to the terms and conditions set forth in this agreement, Kinexum grants you a non-exclusive, limited right to access, use, and display this site and the materials thereon. You agree not to interrupt the operation of this site or its contents in any way.

Confidential information:

Kinexum does not want or require, and you should not, send any confidential or proprietary information to the Kinexum web site. You agree that any information that you or your agents provide to us are not considered confidential or proprietary and will not be in any way defamatory, threatening, obscene, harassing, or otherwise unlawful and will not include the proprietary information of another. Kinexum is free to use information available to the site as unrestricted, irrevocable, worldwide, a royalty-free license to use, reproducible for public display, transmittable, and available for distribution.

Limitation of Liability

IN NO EVENT SHALL KINEXUM OR ANY OF ITS SUBSIDIARIES OR REPRESENTATIVES BE LIABLE TO ANY INDIVIDUAL OR ENTITY FOR ANY DIRECT, INDIRECT, SPECIAL, CONSEQUENTIAL, OR OTHER INJURIES OR DAMAGES INCLUDING, WITHOUT LIMITATION, ANY LOST PROFITS, BUSINESS INTERRUPTION, LOSS OF INFORMATION OR PROGRAMS OR OTHER DATA ON YOUR INFORMATION HANDLING SYSTEM THAT ARE RELATED TO THE USE OF, OR THE INABILITY TO USE, THE CONTENT, MATERIALS, AND FUNCTIONS ON THIS SITE OR ANY LINKED WEB SITE, EVEN IF KINEXUM IS EXPRESSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Changes:

Kinexum reserves the right, at its sole discretion, to change, modify, add, or remove any portion of this agreement, whole or in part, at any time. Kinexum may also impose limits on certain parts of the site and may terminate the authorization and/or rights of license given above.

Terms of Use

By using the Kinexum web site, you have indicated your agreement to these terms of use:

  • The materials available on this site, including materials linked from other sites, are provided without warranties of any kind, expressed or implied. Kinexum does not warrant that the materials will be error free, nor free of viruses, defamatory, offensive, or other harmful content.
  • This site is copyrighted. It is for your personal and non-commercial use. No portion of this site can be copied, modified, transmitted, distributed, or otherwise used without express permission from Kinexum or the content owners. This include use of trademarks, service marks, and trade names.
  • You agree to defend, indemnify, and hold Kinexum and our affiliates, representatives, and subsidiaries harmless from and against any and all losses, liabilities, damages, and expenses, including attorney's fees, arising out of your use of this site.